This site is intended for healthcare professionals

Sol-Gel Technologies provides update on delayed FDA review of Epsolay, a proposed treatment for rosacea.

Read time: 1 mins
Last updated:20th Dec 2021
Published:28th Apr 2021
Sol-Gel Technologies, Ltd. announced an update regarding the FDA approval process for Epsolay (benzoyl peroxide) 5% topical cream for the treatment of Inflammatory lesions of rosacea in adults. In September of 2020, Sol-Gel was informed by the FDA that the PDUFA goal date for Epsolay is April 26, 2021. Subsequently, the COVID-19 pandemic restricted the FDA’s ability to conduct pre-approval inspections. In our most recent written communication with the FDA regarding Epsolay, the final content of the labeling was discussed and agreed to. As of today, Sol-Gel has received no notification from the FDA, but did receive email confirmation that that action on the NDA for Epsolay could not be taken since a pre-approval inspection of the production site of EpsolayY still needs to be conducted.
Condition: Rosacea
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights